2.50
Hdl Handle:
http://hdl.handle.net/2336/47038
Title:
Review article: rabeprazole's tolerability profile in clinical trials
Authors:
Thjodleifsson, B; Cockburn, I
Citation:
Aliment. Pharmacol. Ther. 1999, 13 Suppl 5:17-23
Issue Date:
1-Oct-1999
Abstract:
Rabeprazole is a new member of a class of substituted benzimidazole drugs known as proton pump inhibitors. Comparative trials have demonstrated that it is at least as effective as omeprazole for the treatment of gastrooesophageal reflux disease (GERD), duodenal ulcers, or gastric ulcers. It is significantly more effective than histamine2-receptor antagonists for acid suppression, GERD healing and pain relief, and duodenal ulcer healing and pain relief. Adverse events reported during clinical trials provide an important indication of a medication's tolerability. We demonstrate that rabeprazole has a favourable adverse events profile. It is well tolerated in placebo-controlled studies and comparative trials with omeprazole and H2-receptor antagonists. Moreover, no dose adjustments are required for special populations, such as the elderly or patients with renal or mild-to-moderate hepatic disease. Adverse events data from clinical trials support the use of rabeprazole as a treatment for acid-related diseases.
Description:
To access publisher full text version of this article. Please click on the hyperlink in Additional Links field
Additional Links:
http://dx.doi.org/10.1046/j.1365-2036.1999.00035.x

Full metadata record

DC FieldValue Language
dc.contributor.authorThjodleifsson, B-
dc.contributor.authorCockburn, I-
dc.date.accessioned2009-01-05T13:12:07Z-
dc.date.available2009-01-05T13:12:07Z-
dc.date.issued1999-10-01-
dc.date.submitted2009-01-05-
dc.identifier.citationAliment. Pharmacol. Ther. 1999, 13 Suppl 5:17-23en
dc.identifier.issn0269-2813-
dc.identifier.pmid10555605-
dc.identifier.doi10.1046/j.1365-2036.1999.00035.x-
dc.identifier.urihttp://hdl.handle.net/2336/47038-
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractRabeprazole is a new member of a class of substituted benzimidazole drugs known as proton pump inhibitors. Comparative trials have demonstrated that it is at least as effective as omeprazole for the treatment of gastrooesophageal reflux disease (GERD), duodenal ulcers, or gastric ulcers. It is significantly more effective than histamine2-receptor antagonists for acid suppression, GERD healing and pain relief, and duodenal ulcer healing and pain relief. Adverse events reported during clinical trials provide an important indication of a medication's tolerability. We demonstrate that rabeprazole has a favourable adverse events profile. It is well tolerated in placebo-controlled studies and comparative trials with omeprazole and H2-receptor antagonists. Moreover, no dose adjustments are required for special populations, such as the elderly or patients with renal or mild-to-moderate hepatic disease. Adverse events data from clinical trials support the use of rabeprazole as a treatment for acid-related diseases.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://dx.doi.org/10.1046/j.1365-2036.1999.00035.xen
dc.subject.mesh2-Pyridinylmethylsulfinylbenzimidazolesen
dc.subject.meshAnti-Ulcer Agentsen
dc.subject.meshBenzimidazolesen
dc.subject.meshClinical Trials as Topicen
dc.subject.meshEnzyme Inhibitorsen
dc.subject.meshHumansen
dc.subject.meshOmeprazoleen
dc.subject.meshRandomized Controlled Trials as Topicen
dc.titleReview article: rabeprazole's tolerability profile in clinical trialsen
dc.typeArticleen
dc.contributor.departmentDepartment of Gastroenterology, National Hospital, Reykjavik, Iceland. bjarnit@rsp.isen
dc.identifier.journalAlimentary pharmacology & therapeuticsen

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.